# Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

> **NCT00387933** · PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 37 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** hydroxyurea
- **DRUG:** imatinib mesylate
- **DRUG:** vatalanib

## Key facts

- **NCT ID:** NCT00387933
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387933, "Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00387933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*